Wave Life Sciences Ltd. Q3 2026 Earnings Recap

Wave shares rose 7.5% after earnings, as investors appeared to reward progress in its pipeline—particularly the initiation of a WVE-007 combination trial and a GSK-selected siRNA candidate. The quarter’s key near-term catalyst remains pending: 600-mg WVE-007 data are expected this quarter.

Key Takeaways

• WVE-007’s Phase I single-dose study showed reductions in visceral and total fat, lean-mass preservation, favorable tolerability, and dose-dependent activin E suppression, according to management.
• Wave expects Phase I data for the 600-mg dose this quarter to further characterize potency, duration, safety, and tolerability.
• The company initiated a Phase II-A combination trial of WVE-007 with weekly tirzepatide in people with BMI of 35–50 and type 2 diabetes.
• Wave is also evaluating WVE-007 as monotherapy in a higher-BMI population and as post-incretin maintenance therapy; management says the monotherapy study will assess cardiometabolic biomarkers, including liver fat.
• GSK selected an siRNA development candidate to transition into its pipeline during the quarter.